Medy Tox (Korea) Performance
| 086900 Stock | KRW 133,900 1,600 1.18% |
Medy Tox has a performance score of 5 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.24, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Medy Tox are expected to decrease at a much lower rate. During the bear market, Medy Tox is likely to outperform the market. Medy Tox right now secures a risk of 2.06%. Please verify Medy Tox downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to decide if Medy Tox will be following its current price movements.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Medy Tox are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Medy Tox may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Total Cashflows From Investing Activities | -27.8 B |
Medy |
Medy Tox Relative Risk vs. Return Landscape
If you would invest 12,400,000 in Medy Tox on December 20, 2024 and sell it today you would earn a total of 990,000 from holding Medy Tox or generate 7.98% return on investment over 90 days. Medy Tox is generating 0.1556% of daily returns and assumes 2.0589% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than Medy, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medy Tox Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medy Tox's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medy Tox, and traders can use it to determine the average amount a Medy Tox's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0756
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 086900 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.06 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.16 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 5 95% of assets perform better |
Based on monthly moving average Medy Tox is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medy Tox by adding it to a well-diversified portfolio.
Medy Tox Fundamentals Growth
Medy Stock prices reflect investors' perceptions of the future prospects and financial health of Medy Tox, and Medy Tox fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medy Stock performance.
| Return On Equity | 0.053 | |||
| Return On Asset | 0.0304 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 989.66 B | |||
| Shares Outstanding | 5.44 M | |||
| Price To Earning | 57.74 X | |||
| Price To Sales | 3.96 X | |||
| Revenue | 184.87 B | |||
| EBITDA | 45.66 B | |||
| Cash And Equivalents | 71.77 B | |||
| Total Debt | 55.38 B | |||
| Debt To Equity | 32.80 % | |||
| Book Value Per Share | 21,777 X | |||
| Cash Flow From Operations | 19.97 B | |||
| Earnings Per Share | 1,813 X | |||
| Total Asset | 577.7 B | |||
| Retained Earnings | 131.23 B | |||
| Current Asset | 92.22 B | |||
| Current Liabilities | 54.22 B | |||
About Medy Tox Performance
By analyzing Medy Tox's fundamental ratios, stakeholders can gain valuable insights into Medy Tox's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Medy Tox has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medy Tox has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Medy-Tox Inc., a biopharmaceutical company, develops, manufactures, markets, and sells botulinum toxin and hyaluronic acid dermal filler products primarily in South Korea. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea. MedyTox is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Medy Tox performance evaluation
Checking the ongoing alerts about Medy Tox for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medy Tox help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 27.0% of the company shares are owned by insiders or employees |
- Analyzing Medy Tox's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medy Tox's stock is overvalued or undervalued compared to its peers.
- Examining Medy Tox's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medy Tox's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medy Tox's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medy Tox's stock. These opinions can provide insight into Medy Tox's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Medy Stock analysis
When running Medy Tox's price analysis, check to measure Medy Tox's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medy Tox is operating at the current time. Most of Medy Tox's value examination focuses on studying past and present price action to predict the probability of Medy Tox's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medy Tox's price. Additionally, you may evaluate how the addition of Medy Tox to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |